Lesley Conrad

Dr. Lesley Conrad

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2018 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
LCLesley Conrad
Lesley Conrad
HAHaitham Awdeh
Haitham Awdeh
SAStefany Acosta‐Torres
Stefany Acosta‐Torres
SCSteven Conrad
Steven Conrad
ABApril A. Bailey
April A. Bailey
JLJayanthi Lea
Jayanthi Lea

15 May 2026 in Communications Biology
Verified
Journal Article
Open access
LCLesley Conrad
Lesley Conrad
SYShiwei Yin
Shiwei Yin
BFBingru Feng
Bingru Feng
LKLaShalle King
LaShalle King
BHBrenna Hobson
Brenna Hobson
YFYusi Fu
Yusi Fu
Endometrial cancer (EC) development is driven by the interaction between the tumor and the microenvironment. However, the immune microenvironment dynamics during this process are not clear. Here, we applied single-cell RNA sequencing (scRNA-seq) to uterine blood samples collected at hysterectomy from 15 individuals encompassing four groups-benign controls, endometrial intraepithelial neoplasia (EIN), the transition from EIN to carcinoma, and EC. Uterine blood, obtained without prior enrichment, provides a liquid biopsy of the local tumor milieu, enabling high-resolution profiling of both immune and stromal cells in a minimally invasive manner. Our analysis revealed simultaneous immune and stromal remodeling in early premalignant lesions. Notably, even in EIN, we observed significant immune cell reprogramming alongside the emergence of protumorigenic stromal-epithelial interactions. Importantly, we discovered predictive single-cell transcriptomic signatures derived from neutrophils that stratify patients according to disease state, highlighting the potential of tumor-educated innate immune cells as biomarkers. These findings yield candidate cellular and molecular signatures, particularly from neutrophils, that could enhance early EC detection and guide therapeutic strategies. Our work provides a proof-of-concept for leveraging local liquid biopsies in single-cell oncology, offering new insights into EC initiation and development, paving the way for noninvasive diagnostics on the basis of single-cell transcriptomic profiles.

Verified
Journal Article
Open access
PDF file
MDMichael Patrick Dempsey
Michael Patrick Dempsey
KAKatelyn E. Andersen
Katelyn E. Andersen
BWBrittney M. Wells
Brittney M. Wells
MTMitchell A. Taylor
Mitchell A. Taylor
CCClay L. Cashman
Clay L. Cashman
RFRobin Farias-Eisner
Robin Farias-Eisner
Epithelial adenocarcinoma of the ovary and colon are associated with the highest rates of cancer-related deaths in women in the U.S. The literature supports the role of HDL-associated apolipoproteins in the treatment of cancer and other pro-inflammatory diseases. Previously, we developed a novel 20-amino acid mimetic peptide, HM-10/10, which potently inhibits tumor development and growth in colon and ovarian cancer. Here, we report the properties of HM-10/10 relative to its stability in vitro. The results demonstrated that HM-10/10 had the highest half-life in human plasma compared to plasma from other species tested. HM-10/10 demonstrated stability in human plasma and simulated gastric environment, increasing its promise as an oral pharmaceutical. However, under conditions modeling the small intestine, HM-10/10 demonstrated significant degradation, likely due to the peptidases encountered therein. Furthermore, HM-10/10 demonstrated no evidence of time-dependent drug–drug interactions, although it demonstrated CYP450 induction slightly above cutoff. As proteolytic degradation is a common limitation of peptide-based therapeutics, we are pursuing strategies to improve the stability properties of HM-10/10 by extending its bioavailability while retaining its low toxicity profile. HM-10/10 holds promise as a new agent to address the international women’s health crisis of epithelial carcinomas of the ovary and colon.

29 September 2025 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
ELElena Lucas
Elena Lucas
KMKyle Molberg
Kyle Molberg
LCLesley Conrad
Lesley Conrad
SNShuang Niu
Shuang Niu
HCHao Chen
Hao Chen
Background: Gynandroblastoma is an exceptionally rare ovarian sex cord-stromal tumor containing both male and female components. Due to its rarity, molecular data are limited, and its clinical behavior remains incompletely understood. Methods: We retrospectively analyzed 2 tumors of gynandroblastoma diagnosed at 2 teaching hospitals. Clinicopathological data, including patient demographics, tumor characteristics, and outcomes, were collected. Immunohistochemistry (IHC) and next-generation sequencing (NGS) were performed on both tumors to evaluate for the presence of FOXL2 (Forkhead Box L2) and/or DICER1 (dicer 1, ribonuclease III) mutations. Results: Both tumors were FIGO stage IA . Microscopically, tumor #1 contained well-differentiated Sertoli cell tumor (SCT) and adult-type granulosa cell tumor (AGCT) components, while tumor #2 comprised moderately differentiated Sertoli-Leydig cell tumor (SLCT) and AGCT components. Immunophenotypically, both tumors were positive for the sex cord-stromal markers calretinin and inhibin. NGS revealed the absence of FOXL2 c.402C>G (p.Cys134Trp) in both tumors. DICER1 mutations were absent in both tumors. Both patients remained disease-free during follow-up periods of 6 and 62 months, respectively. Conclusion: Gynandroblastoma remains a distinct and rare entity with characteristic histopathological and molecular features. Our findings align with previous studies, emphasizing the rarity of FOXL2 mutation and the absence of DICER1 mutations in tumors with an AGCT component, regardless of the male sex cord component. Further studies are needed to better understand its molecular pathogenesis and long-term outcomes.

21 June 2026 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
JCJohn J. Coté
John J. Coté
RCRemington D. Coté
Remington D. Coté
KKKeara Kennedy
Keara Kennedy
MBMatthew S. Block
Matthew S. Block
RFRobin Farias-Eisner
Robin Farias-Eisner
LCLesley Conrad
Lesley Conrad

26 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
MSMorgan Sainsbury
Morgan Sainsbury
CWClayton Watts
Clayton Watts
DHDaniela Hinchman-Dominguez
Daniela Hinchman-Dominguez
LCLesley Conrad
Lesley Conrad
Background: Sarcomatoid carcinoma is an aggressive, rare malignancy that can arise as mural nodules in the presence of other primary ovarian malignancies. Associated with sarcomatoid carcinomas of other organs, paraneoplastic leukemoid reaction (PRL) is a rare syndrome of extreme hyperleukocytosis, usually greater than 50 k/ul, that arises in the absence of a primary hematologic malignancy and characteristically resolves following tumor removal. Case Presentation: A 57-year-old female presented with vague gastrointestinal symptoms and was incidentally found to have white blood cell (WBC) of 56.4 k/ul, with a negative work-up for hematologic malignancy. Abdominal CT imaging demonstrated a large abdominal mass and biopsy confirmed a diagnosis of sarcomatoid carcinoma, clinically favored to be of ovarian origin. Treatment consisted of surgical resection of the large (32 x 30 x 17 cm) mass, left salpingo-oophorectomy, and radical small bowel resection. Notably, the patient’s WBC count fell from 175 k/ul, on the morning of surgery, to 17.3 k/ul, days after tumor resection. Conclusion: We report a rare case of sarcomatoid carcinoma of probable ovarian origin, presenting with extreme leukocytosis and characteristic behavior of PRL. Sarcomatoid carcinoma and PRL are both, individually, associated with a poor prognosis. Accurate diagnosis is essential to ensure minimal delay in initiating treatment.